Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30443% above fair value
$286.85−0.09 (-0.03%)
Close on Nov 20, 2026Market cap $5.74BP/E 125.3Yield –
Ligand Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Ligand Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was $25.52M, up 41.9% year over year. For fiscal 2025 it was $41.00M. Over ten years it grew 4.1% a year on average. The highest annual figure on record is $807.08M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.00M | – |
| FY2024 | Dec 31, 2024 | -$22.61M | -289.3% |
| FY2023 | Dec 31, 2023 | $11.94M | +293.2% |
| FY2022 | Dec 31, 2022 | $3.04M | -97.1% |
| FY2021 | Dec 31, 2021 | $103.85M | +176.9% |
| FY2020 | Dec 31, 2020 | $37.50M | -95.4% |
| FY2019 | Dec 31, 2019 | $807.08M | +392.9% |
| FY2018 | Dec 31, 2018 | $163.73M | +140.5% |
| FY2017 | Dec 31, 2017 | $68.08M | +55.1% |
| FY2016 | Dec 31, 2016 | $43.89M | +60.6% |
| FY2015 | Dec 31, 2015 | $27.33M | +39.2% |
| FY2014 | Dec 31, 2014 | $19.63M | +31.3% |
| FY2013 | Dec 31, 2013 | $14.94M | +7642.5% |
| FY2012 | Dec 31, 2012 | $193.00K | – |
| FY2011 | Dec 31, 2011 | -$878.00K | – |
| FY2010 | Dec 31, 2010 | -$29.30M | – |
| FY2009 | Dec 31, 2009 | -$9.97M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$15.76M | -128.5% |
| Q2 FY2026 | Jun 30, 2026 | $8.59M | +1.7% |
| Q1 FY2026 | Mar 31, 2026 | $17.37M | – |
| Q4 FY2025 | Dec 31, 2025 | $15.32M | – |
| Q3 FY2025 | Sep 30, 2025 | $55.39M | +1662.2% |
| Q2 FY2025 | Jun 30, 2025 | $8.44M | – |
| Q1 FY2025 | Mar 31, 2025 | -$36.22M | -1312.0% |
| Q4 FY2024 | Dec 31, 2024 | -$9.64M | – |
| Q3 FY2024 | Sep 30, 2024 | $3.14M | +2.1% |
| Q2 FY2024 | Jun 30, 2024 | -$19.10M | – |
| Q1 FY2024 | Mar 31, 2024 | $2.99M | -79.0% |
| Q4 FY2023 | Dec 31, 2023 | -$3.36M | – |
| Q3 FY2023 | Sep 30, 2023 | $3.08M | -75.1% |
| Q2 FY2023 | Jun 30, 2023 | -$1.98M | -122.9% |
| Q1 FY2023 | Mar 31, 2023 | $14.21M | +566.0% |
| Q4 FY2022 | Dec 31, 2022 | -$20.10M | -153.3% |
| Q3 FY2022 | Sep 30, 2022 | $12.34M | -21.4% |
| Q2 FY2022 | Jun 30, 2022 | $8.66M | -81.1% |
| Q1 FY2022 | Mar 31, 2022 | $2.13M | -54.8% |
| Q4 FY2021 | Dec 31, 2021 | $37.69M | +64.8% |
| Q3 FY2021 | Sep 30, 2021 | $15.71M | +319.2% |
| Q2 FY2021 | Jun 30, 2021 | $45.74M | +544.2% |
| Q1 FY2021 | Mar 31, 2021 | $4.72M | +24.5% |
| Q4 FY2020 | Dec 31, 2020 | $22.87M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.75M | – |
| Q2 FY2020 | Jun 30, 2020 | $7.10M | – |
| Q1 FY2020 | Mar 31, 2020 | $3.79M | -99.5% |
| Q4 FY2019 | Dec 31, 2019 | -$10.18M | -130.7% |
| Q3 FY2019 | Sep 30, 2019 | -$5.16M | -122.1% |
| Q2 FY2019 | Jun 30, 2019 | -$4.13M | -105.9% |
| Q1 FY2019 | Mar 31, 2019 | $826.54M | +2131.4% |
| Q4 FY2018 | Dec 31, 2018 | $33.15M | +16.9% |
| Q3 FY2018 | Sep 30, 2018 | $23.36M | +41.6% |
| Q2 FY2018 | Jun 30, 2018 | $70.18M | +439.2% |
| Q1 FY2018 | Mar 31, 2018 | $37.04M | +262.6% |
| Q4 FY2017 | Dec 31, 2017 | $28.35M | +46.5% |
| Q3 FY2017 | Sep 30, 2017 | $16.49M | – |
| Q2 FY2017 | Jun 30, 2017 | $13.02M | – |
| Q1 FY2017 | Mar 31, 2017 | $10.22M | – |
| Q4 FY2016 | Dec 31, 2016 | $19.36M | – |
See a number that looks wrong?